Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease

dc.authorid0000-0002-4349-9193
dc.contributor.authorKanbay, Mehmet
dc.contributor.authorSolak, Yalcin
dc.contributor.authorUnal, Hilmi Umut
dc.contributor.authorKurt, Yasemin Gulcan
dc.contributor.authorGok, Mahmut
dc.contributor.authorCetinkaya, Hakki
dc.contributor.authorKaraman, Murat
dc.date.accessioned2025-05-10T19:47:35Z
dc.date.issued2014
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractPrevious studies showed that renal dysfunction was associated with both a reduction in serum high-density lipoprotein (HDL) cholesterol concentration and increased circulating monocyte count. We aimed to investigate the effect of circulating monocyte to serum HDL cholesterol ratio (M/H ratio) on fatal and composite cardiovascular events, in an observational cohort study of chronic kidney disease (CKD) patients. A total of 340 subjects with stage 1-5 CKD were followed for a mean follow-up period of 33 (range 2-44) months and assessed for fatal and nonfatal CV events. M/H ratio was calculated for all patients. All-cause mortality and CVE were also analyzed in relation to M/H ratio. Monocyte/HDL cholesterol ratio was negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.43, P < 0.001). Notably, both fatal and combined fatal and nonfatal cardiovascular events were more common in patients having a M/H ratio in the third tertile was associated with a hazard ratio of 2.24 and 4.91, respectively, for fatal and composite cardiovascular events compared to being in the first tertile. Monocyte/HDL cholesterol ratio was increased with decreasing eGFR in predialytic CKD patients. Most importantly, we report for the first time that an increased M/H ratio was cross-sectionally associated with a worse cardiovascular profile and arose as independent predictors of major cardiovascular events during follow-up.
dc.identifier.doi10.1007/s11255-014-0730-1
dc.identifier.endpage1625
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue8
dc.identifier.pmid24853998
dc.identifier.scopus2-s2.0-84906937455
dc.identifier.scopusqualityQ2
dc.identifier.startpage1619
dc.identifier.urihttps://doi.org/10.1007/s11255-014-0730-1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11437
dc.identifier.volume46
dc.identifier.wosWOS:000340523800022
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofInternational Urology and Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectMonocyte/HDL cholesterol ratio
dc.subjectCardiovascular disease
dc.subjectChronic kidney disease
dc.subjectMonocyte
dc.subjectHDL cholesterol
dc.titleMonocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease
dc.typeArticle

Dosyalar